UCB Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:UCB Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014079
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
UCB Inc (UCB), a subsidiary of UCB SA is a healthcare solutions provider that offers therapeutics. The company develops products with an emphasis on central nervous system and immunology therapeutic domains. Its products include cimzia, vimpat, keppra XR, neupro, tussionex pennkinetic, metadate CD, and others. UCB’s products are used in the treatment of partial onset seizures, rheumatoid arthritis, attention deficit hyperactivity disorder and cough and upper respiratory symptoms associated with allergy or a cold. The company also conducts research and development to upgrade its products according to market requirements. It offers several health programs for patients, healthcare professionals and caregivers. The company operates through research triangle park located in North Carolina. UCB is headquartered in Smyrna, Georgia, the US.

UCB Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
UCB Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
UCB Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
UCB Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
UCB Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
UCB Inc, Medical Devices Deals, 2011 to YTD 2017 9
UCB Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
UCB Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Clementia Pharma Secures USD60 Million Venture Financing 11
Partnerships 13
Evotec Partners with UCB 13
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 14
UCB Enters Into Research Collaboration With Katholieke Universiteit Leuven 15
UCB Enters Into Co-Development Agreement With Harvard University 16
Licensing Agreements 17
UCB Exercises Option for Licensing Agreement with Oncodesign 17
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 18
UCB Inc – Key Competitors 19
UCB Inc – Key Employees 20
UCB Inc – Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
UCB Inc, Pharmaceuticals & Healthcare, Key Facts 2
UCB Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
UCB Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
UCB Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
UCB Inc, Deals By Therapy Area, 2011 to YTD 2017 8
UCB Inc, Medical Devices Deals, 2011 to YTD 2017 9
UCB Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Clementia Pharma Secures USD60 Million Venture Financing 11
Evotec Partners with UCB 13
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 14
UCB Enters Into Research Collaboration With Katholieke Universiteit Leuven 15
UCB Enters Into Co-Development Agreement With Harvard University 16
UCB Exercises Option for Licensing Agreement with Oncodesign 17
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 18
UCB Inc, Key Competitors 19
UCB Inc, Key Employees 20

★海外企業調査レポート[UCB Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Philippine Long Distance Telephone Company:企業の戦略・SWOT・財務情報
    Philippine Long Distance Telephone Company - Strategy, SWOT and Corporate Finance Report Summary Philippine Long Distance Telephone Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Bridgford Foods Corporation:企業の戦略・SWOT・財務情報
    Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Global Blood Therapeutics Inc (GBT):企業の財務・戦略的SWOT分析
    Summary Global Blood Therapeutics Inc (GBT) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel oral medicines for the treatment of grievous blood-based disorders. The company's lead drug candidate GBT440 is an oral, small molecule drug for the treatment o …
  • Mahaweli Reach Hotels Plc:企業の戦略・SWOT・財務分析
    Mahaweli Reach Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary Mahaweli Reach Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Cheung Kong Infrastructure Holdings Ltd:企業の戦略・SWOT・財務情報
    Cheung Kong Infrastructure Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Cheung Kong Infrastructure Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Damas International Ltd:企業の戦略・SWOT・財務分析
    Damas International Ltd - Strategy, SWOT and Corporate Finance Report Summary Damas International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ability Pharmaceuticals SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Ability Pharmaceuticals SL (Ability Pharma), formerly AB Therapeutics SL is a biopharmaceutical company that discovers and develops human therapeutics for the treatment of cancer and other indications. The company’s lead pipeline drug candidate includes ABTL0812, a new drug class of small mo …
  • Dow Jones & Co Inc:企業の戦略的SWOT分析
    Dow Jones & Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • City Developments Ltd:企業の戦略・SWOT・財務情報
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nakheel
    Nakheel - Strategy, SWOT and Corporate Finance Report Summary Nakheel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Coca-Cola Amatil Limited:戦略・SWOT・企業財務分析
    Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola Amatil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Immune Pharmaceuticals Inc (IMNP):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designe …
  • Etrion Corp (ETX):企業の財務・戦略的SWOT分析
    Summary Etrion Corp (Etrion) formerly PetroFalcon Corp, is a solar energy development company. The company produce power and builds, owns and operates utility-scale solar power generation plants. It develops greenfield solar power projects in Japan and Chile. Etrion owns and operates 56.7 MW of sola …
  • Range Resources Ltd (RRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Resources Ltd (Range Resources) is an independent upstream oil and gas company. It explores, develops and produces oil and gas in Georgia, Guatemala and Trinidad. The company works on both onshore and offshore production and its onshore projects are operational through water injection. …
  • Bioasis Technologies Inc (BTI):企業の財務・戦略的SWOT分析
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Pharmascience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmascience Inc (Pharmascience) is a pharmaceutical company which develops, manufactures and markets generic pharmaceutical products. The company offers generic, prescription, over-the-counter and private label OTC products. It offers drugs in therapeutic areas of anti-inflammatory, cancer …
  • Societe Generale S.A.:企業の戦略・SWOT・財務分析
    Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report Summary Societe Generale S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Plenus Company Limited:企業の戦略・SWOT・財務情報
    Plenus Company Limited - Strategy, SWOT and Corporate Finance Report Summary Plenus Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Catalyst Biosciences Inc (CBIO):企業の財務・戦略的SWOT分析
    Summary Catalyst Biosciences Inc (Catalyst Biosciences), formerly Targacept Inc, is a clinical-stage biopharmaceutical company that develops protease-based advanced medicines to treat hematological indications. The company specializes in hemostasis, with focus on subcutaneous prophylaxis of hemophil …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆